ロード中...
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti‐Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
On November 23, 2015, the U.S. Food and Drug Administration approved nivolumab (OPDIVO, Bristol‐Myers Squibb Company) for patients with advanced renal cell carcinoma (RCC) who have received prior anti‐angiogenic therapy. The approval was based on efficacy and safety data demonstrated in an open‐labe...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5344649/ https://ncbi.nlm.nih.gov/pubmed/28232599 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0476 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|